— Product aims to disrupt the autoimmune attack against insulin-producing beta cells
June 15, 2026
• 2 min read
The FDA expanded the approval of teplizumab (Tzield) to include pediatric patients 8 years and older who have recently been diagnosed with stage 3 type 1 diabetes, the clinical stage where hyperglycemia symptoms emerge and insulin therapy is needed.
An anti-CD3 antibody, teplizumab is indicated to delay the decline of insulin production and is believed to work by deactivating the immune cells that attack insulin-producing beta cells while increasing the proportion of cells that help moderate the immune response.
